[Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma].
D001549:Benzamides; D002830:Choroid Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging; D002924:Ciliary Body; D003230:Conjunctival Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging; D003937:Diagnosis, Differential; D005134:Eye Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000556:secondary*; D009887:Ophthalmoscopy; D011237:Predictive Value of Tests; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D012878:Skin Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D014057:Tomography, X-Ray Computed; D014463:Ultrasonography; D014604:Uveal Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging
D001549:Benzamides; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; C066918:N-(2-(diethylamino)ethyl)-4-iodobenzamide
Etude clinique en phase 2 de la BZA2 (123IN-(2-diéthylaminoéthyl)-2-iodobenzamide) dans le diagnostic du mélanome malin oculaire et de ses métastases.